EUVIMEDOpdag EUVIMED
Crossref

Design and synthesis of Fsp 3 ‐enriched spirocyclic‐substituted diarylpyrimidine derivatives as novel HIV ‐1 NNRTIs

Zihao Sang, Tao Zhang, Zhao Wang iD, Erik De Clercq iD, Christophe Pannecouque, Dongwei Kang, Peng Zhan iD, Xinyong Liu iD

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14510 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2024. Written by Zihao Sang and 7 co-authors. Institution: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of …. Major MEDLINE topics: HIV-1, Anti-HIV Agents. Cited 1 times so far (Crossref); 28 references. Funded by: National Natural Science Foundation of China, Shandong Provincial Natural Science Foundation, Qilu Young Scholars Program of Shandong University and Taishan Scholar Program at Shandong Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In this study, a novel series of diarylpyrimidine derivatives with Fsp 3 ‐enriched spirocycles were designed and synthesized to further explore the chemical space of the hydrophobic channel of the NNRTI‐binding pocket. The biological evaluation results showed that most of the compounds displayed effective inhibitory potency against the HIV‐1 wild‐type strain, with EC 50 values ranging from micromolar to submicromolar levels. Among them, TT6 turned out to be the most effective inhibitor with an EC 50 value of 0.17 μM, demonstrating up to 47 times more active than that of reference drug 3TC (EC 50 = 8.01 μM). More encouragingly, TT6 was found to potently inhibit the HIV‐1 mutant strain K103N with an EC 50 value of 0.69 μM, being about 6‐fold more potent than 3TC (EC 50 = 3.68 μM) and NVP (EC 50 = 4.62 μM). Furthermore, TT6 exhibited the most potent inhibitory activity toward HIV‐1 reverse transcriptase with an IC 50 value of 0.33 μM. Additionally, molecular simulation studies were conducted to investigate the binding modes between TT6 and NNRTI‐binding pocket, which may provide valuable clues for the follow‐up structural optimizations.

Subjects

MeSH terms (MEDLINE)

HIV-1Anti-HIV AgentsStructure-Activity RelationshipDrug DesignReverse Transcriptase InhibitorsMolecular Docking SimulationHIV Reverse Transcriptase

Author keywords

DAPYsHIV‐1 RTNNRTIshydrophobic channelspirocyclic

Substances

Anti-HIV AgentsReverse Transcriptase InhibitorsHIV Reverse Transcriptase

Authors and institutions

  • Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • China-Belgium Collaborative Research Center for Innovative Antiviral Drugs of Shandong Province, Jinan, Shandong, China.
  • Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Leuven, Belgium.

ORCID profiles: Zhao Wang, Erik De Clercq, Peng Zhan, Xinyong Liu

Funding

  • National Natural Science Foundation of China
  • Shandong Provincial Natural Science Foundation
  • Qilu Young Scholars Program of Shandong University and Taishan Scholar Program at Shandong Province
  • Natural Science Foundation of Shandong Province

Cite

APA

Sang, Z., Zhang, T., Wang, Z., De Clercq, E., Pannecouque, C., Kang, D., Zhan, P., & Liu, X. (2024). Design and synthesis of Fsp 3 ‐enriched spirocyclic‐substituted diarylpyrimidine derivatives as novel HIV ‐1 NNRTIs. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14510

Vancouver

Sang Z, Zhang T, Wang Z, De Clercq E, Pannecouque C, Kang D, et al. Design and synthesis of Fsp 3 ‐enriched spirocyclic‐substituted diarylpyrimidine derivatives as novel HIV ‐1 NNRTIs. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14510

BibTeX
@article{Sang2024,
  author = {Sang, Zihao and Zhang, Tao and Wang, Zhao and De Clercq, Erik and Pannecouque, Christophe and Kang, Dongwei and Zhan, Peng and Liu, Xinyong},
  title = {Design and synthesis of Fsp 3 ‐enriched spirocyclic‐substituted diarylpyrimidine derivatives as novel HIV ‐1 NNRTIs},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14510}
}
Start for free →